Mannkind opened lower at $4.15, compared with its previous close of $4.19. In the last trading session, the stock traded between $4.11 and $4.24. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Mannkind is now worth
$ 83.83
Resulting in a loss of
$ 16.17 (16.17%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 8 Analysts
Buy
87.5%
Hold
12.5%
Sell
0%
Markets Today
Today's Change
$-0.03 (-0.76%)
Day High
$4.24
Day Low
$4.11
Day Open
$4.15
Prev Close
$4.19
Volume
19,56,752
1W Return
5.69%
1M Return
33.06%
3M Return
7.86%
6M Return
23.75%
1Y Return
-20.80%
Fundamentals
Market Cap ($ Mn)
1,337
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
8.15%
EPS (TTM)
$-0.07
Investment Returns
1 Week
5.69%
1 Month
33.06%
3 Months
7.86%
6 Months
23.75%
9 Months
-27.56%
Financials
Quarterly
All values in $ Mn
76.5
Jun 25
82.1
Sep 25
112.0
Dec 25
90.2
Mar 26
109.4
Jun 26
101.9
Sep 26
Updates
6Nov
Cantor Fitzgerald raises MannKind price target to $10, maintains Overweight
Cantor Fitzgerald raised MannKind's price target from $8 to $10. The firm maintained its Overweight rating on the stock. Analyst Olivia Brayer Saunders issued the revised target.
6 days ago
20Oct
Cantor Fitzgerald maintains Overweight rating on MannKind at $8 target
Cantor Fitzgerald reiterated Overweight rating on MannKind. Price target maintained at $8 per share. Rating action issued by analyst Olivia Brayer Saunders.
23 days ago
12Oct
MannKind Furoscix ReadyFlow shows urine output comparable to IV furosemide
New analyses show Furoscix ReadyFlow delivers urine output comparable to IV furosemide. Consistent bioavailability and diuresis across injection sites support flexible clinical use. Data confirms seamless transition from Furoscix On-body Infusor to ReadyFlow autoinjector. Findings reinforce outpatient management potential for heart failure and CKD fluid overload.
1mo ago
11Sep
Cantor Fitzgerald reiterates Overweight on MannKind, keeps $8 target
Cantor Fitzgerald reiterates Overweight rating on MannKind. Price target maintained at $8 per share. Analyst Olivia Brayer Saunders leads the coverage.
2mo ago
22Aug
MannKind files prospectus for resale of 12.85m shares by stockholders
MannKind files prospectus for resale of 12,853,470 shares. Includes 10,440,838 common shares and 2,412,632 warrant shares. Shares originated from private placement closing July 24, 2026. Company receives no proceeds from this resale transaction.
Wells Fargo analyst Benjamin Burnett raised the price target for MannKind Corp from $11 to $14. The firm maintains its Overweight rating on the stock, signaling continued bullishness on the biotech company's future performance.
